Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18th, 2021

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that President and CEO Nick Colangelo will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18 at 10:00 AM ET. This event aims to showcase advancements in medical technology and health services.

A webcast of the presentation will be accessible on the Investor Relations section of the Vericel website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on Thursday November 18^th, at 10:00a.m. Eastern Time.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

When is Nick Colangelo's presentation at the Canaccord Genuity Forum?

Nick Colangelo's presentation is scheduled for November 18 at 10:00 AM ET.

Where can I watch the Vericel Corporation presentation?

The presentation can be accessed via a webcast in the Investor Relations section of Vericel's website.

What are the main products offered by Vericel Corporation?

Vericel offers MACI® for cartilage repair and Epicel® for burn treatment.

What is the significance of the Canaccord Genuity Forum for Vericel?

The forum allows Vericel to showcase its advancements in medical technology to investors and industry experts.